Protein Cell 5 , 592602 (2014)
Novel therapeutic approaches, including dual and triple incretin receptor agonists, are showing enhanced efficacy in both diabetes and obesity management
Two of these are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)
As each patient's experience is unique, factors such as starting weight, dietary habits, and activity level play a role in the results
Furthermore, substituting FDA-approved medications with non-approved semaglutide products can increase the risk of severe stomach problems and other adverse effects
After 2 weeks Improved balance: With consistent daily use, appetite control often feels more manageable